At this ACR Convergence 2025 session, experts discussed disease management considerations to optimize outcomes in pregnant patients with SLE.
ACR Releases New Guideline for Management of SLE at ACR 2025
Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.
Secrets & Pearls of Rheumatology at ACR Convergence 2025
Two clinical diagnosticians presented their pearls of wisdom for clinical rheumatologists to take forward when managing patients from the clinics to the hospital wards.
Reflections on B Cells in SLE & Lupus Nephritis
At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
B Original: B Cells, Non-Invasive Biomarkers & More
Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.
Atherosclerosis in Patients with SLE & the Risk of Progression: A 10-Year View
Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.
Autoantibodies Illuminate Lupus Nephritis
Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.
Lupus Update: Findings from the Latest Phase 3 Clinical Trials
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
- 1
- 2
- 3
- …
- 13
- Next Page »